CVRx, Inc.
NASDAQ:CVRXMedical - Devices
+$0.11 today
- Market cap
- $69.79M
- Beta
- 0.77
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.30M
CVRX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
CVRx, Inc.NASDAQ: CVRX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.92M rose 18.8% year over year, ahead of the +11.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at +41.7% a year.
Context
- Stock-based compensation amounted to 19.5% of revenue in FY2025, down 17.6 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +18.8% holds above the trailing-twelve-month pace of +11.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 11.05M USD
- Year-over-year change
- -42.0%
- 4-year CAGR
- +55.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.05M | -42.0% |
| FY2024 | 2024-12-31 | 19.05M | +202.2% |
| FY2023 | 2023-12-31 | 6.3M | +62.2% |
| FY2022 | 2022-12-31 | 3.89M | +103.3% |
| FY2021 | 2021-12-31 | 1.91M | — |
Stock-Based Compensation vs competitors
How CVRX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +11.1% is the 4th highest of 10, against a peer median of -14.0%.
- Stock-based compensation amounts to 19.5% of revenue for CVRX, versus a peer median of 14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.14M USD | -10.6% | -2.2% | 9.5% | |
| LTM Mar 2026 | $11.67M USD | -30.6% | +0.2% | 14.7% | |
| LTM Mar 2026 | $11.51M USD | +11.1% | +41.7% | 19.5% | |
| LTM Mar 2026 | $10.59M USD | +14.3% | +5.6% | 26.0% | |
| LTM Mar 2026 | $9.88M USD | -14.0% | +11.0% | 17.1% | |
| LTM Mar 2026 | $9.79M USD | +79.2% | +10.3% | 6.8% | |
| LTM Mar 2026 | $9.27M USD | +29.4% | +20.6% | 3.2% | |
| LTM Dec 2025 | $4.19M USD | -42.3% | -39.2% | 32.2% | |
| LTM Mar 2026 | $2.38M USD | -344.3% | — | 5.4% | |
| LTM Mar 2026 | €2.03M EUR | -21.0% | — | 15.1% | |
| Peer median (excluding CVRX) | — | -14.0% | +5.6% | 14.7% | |
Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.08M) | (41.43M) | (41.2M) | (59.97M) | (53.31M) |
| Depreciation & Amortization | 168K | 412K | 522K | 619K | 756K |
| Deferred Income Tax | 14.62M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.91M | 3.89M | 6.3M | 19.05M | 11.05M |
| Change in Working Capital | (1.58M) | (5.57M) | (4.81M) | 949K | 1M |
| Accounts Receivables | (1.28M) | (2.94M) | (2.05M) | (1.72M) | (1.4M) |
| Inventory | (537K) | (3.08M) | (4.03M) | (1.12M) | (98K) |
| Accounts Payables | 27K | 1.21M | 165K | 698K | 1.25M |
| Other Working Capital | 207K | (761K) | 1.1M | 3.09M | 1.25M |
| Other Non-Cash Items | 229K | 25K | 158K | 203K | 327K |
| Operating Cash Flow | (27.73M) | (42.68M) | (39.02M) | (39.14M) | (40.17M) |
| Capital Expenditures | (1.18M) | (685K) | (591K) | (1.36M) | (580K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.18M) | (685K) | (591K) | (1.36M) | (580K) |
| Debt Repayment | (21.3M) | 7.5M | 22.5M | 20M | 0 |
| Common Stock Issued | 133.16M | 771K | 1.66M | 32.52M | 10.52M |
| Common Stock Repurchased | (1K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 23K | (7K) | 1.48M | 3.35M | 0 |
| Financing Cash Flow | 111.88M | 7.49M | 23.98M | 55.87M | 10.52M |
| Effect of Forex Changes | (8K) | (9K) | 3K | (1K) | 5K |
| Net Change in Cash | 82.96M | (35.88M) | (15.63M) | 15.36M | (30.23M) |
| Free Cash Flow | (28.92M) | (43.36M) | (39.61M) | (40.51M) | (40.75M) |
CVRx, Inc.
NASDAQ:CVRX
Intrinsic Alpha fair value
Locked
Current Price
$2.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.